I have sold all of my shares in Mayne Pharma (ASX:MYX), and despite the coincidental timing I swear it had nothing to do with Valeant. I would in general call this purchase a failure, although I was lucky to sell out without loss. Why sell? I recently had my Mayne Pharma thesis challenged, which was …
reprinted with permission from financialnews.net.com.network.au. Bringing you the hottest news in global finance FNNCNAU reporter Fiona Mastodon recently conducted a live interview with Yeti Bigfoot, founder of controversial activist investment fund 10Foot Capital. 10Foot Capital is in the midst of a major restructuring program as it attempts to rectify market-lagging performance. Here’s the interview transcript for …
There was a pearler of an announcement from the Getswift (ASX: GSW) this morning. I paraphrase: The share price didn’t move after we first announced the contract, therefore our Fruit Box contract was not material When Fruit Box was cancelled, we hadn’t completely finalised our contract with Commbank, but we were sure hoping to, because …
Not being a hotcopper member myself, I ask that people send me good stuff they see on there. I got this hilarious one overnight: I don’t assert that there is anything wrong with Fantastic Furniture or AFR here, but there is a certain humour in having to source a quote from a known fraud (Fantastic’s …
Can you still be a genius if your viewpoint is the same as everybody else in the market? Asking for a friend. You will know that I wrote about Getswift previously. In that post I focused a lot on the company’s deal with Amazon. I made the silly mistake of assuming that the company’s other contracts …
David Lamm, Executive Chairman and Chief Investment Officer of NGE Capital Ltd (ASX: NGE), a 10foot holding, recently agreed to an interview. I’m grateful and appreciative that he took the time to answer the questions of a very small shareholder. Before I get into that, there is obvious potential for an anonymous entity (me) to spruik …
The December quarter’s gone and the 10foot portfolio is finally starting to move in the right direction, albeit still lagging the market quite badly. I am now around 64% invested and have 36% of the portfolio in cash. Here’s my performance for the quarter just gone vs my primary index, the XNT. I am up …
I was hoping to have my December quarterly review out this weekend. I was also hoping to make some progress on either my deep dive on Mongolian stocks or my look at Blue Sky Alternatives (ASX: BLA). I did, but nothing’s ready to publish yet. Instead I did this: If- If you can keep your …
I started looking at Australian-listed Chinese company Dongfang Modern Agriculture (ASX: DFM) more closely after I stumbled across its loan announcement yesterday. Agriculture is well outside my area of expertise, but if I understand the business model correctly, there are a few potential warning signs I’ve spotted (all figures are in AUD unless specified otherwise): Margins …
My position in Probiotec Limited (ASX: PBP) has ripped higher over the past few months, up over 100% since I bought it in June. This has given me a problem and funnily enough I’m more concerned about being up 100% on Probiotec than I was being down 70% on RNY Property Trust (ASX:RNY), my first loser. …